Restart Life Closes Over-Subscribed Second Tranche Financing

Restart Life Sciences Corp. (CSE: HEAL) has successfully closed the over-subscribed second tranche of its non-brokered private placement, raising gross proceeds of CDN$630,000. This follows the company's earlier news releases dated November 12 and December 5, 2025, where it aimed to raise a total of CDN$1,000,000. The overwhelming interest in the company's initiatives allowed it to surpass its goal, culminating in total fundraising of CDN$1,130,000 across both tranches.

In the second tranche, Restart Life issued 6,300,000 units at a price of CDN$0.10 per unit, with each unit consisting of one common share and one transferable common share purchase warrant. These warrants allow holders to purchase additional shares at the same price for a duration of one year. Furthermore, the company distributed 132,000 non-transferable finder warrants to arm's-length finders, which also entitle holders to purchase common shares at CDN$0.10 per share for one year.

The proceeds from this private placement are earmarked for health food trials, potential acquisitions, and general working capital requirements. All securities issued are under a hold period that will expire on April 18, 2026.

Restart Life Sciences is a Canadian-based life sciences company focused on innovative health solutions. Investors and interested parties can find more information on the company's website. The release includes forward-looking statements highlighting the inherent uncertainties and risks associated with the company's anticipated results and performance. The Canadian Securities Exchange does not take responsibility for the accuracy of the information contained in the announcement.

Restart Life Sciences Corp. (CSE: HEAL) has recently completed an over-subscribed second tranche of its financing, raising a total of CDN$630,000, further boosting its overall funds from this offering to CDN$1,130,000. This increased capital is a positive indicator of market confidence in the company’s growth potential, especially as it pertains to health food trials and potential acquisitions.

The company issued 6,300,000 units at CDN$0.10 each, with additional warrants that provide an opportunity for investors to purchase more shares at the same price within the next year. The oversubscription suggests that there is significant interest and trust in Restart Life’s strategic direction and operational plans. With the proceeds earmarked for health food trials, acquisitions, and working capital, Restart Life seems well-positioned to take advantage of the burgeoning health and wellness market.

From an investment perspective, the current pricing structure around CDN$0.10 provides a potentially attractive entry point, especially considering the warranted opportunity to purchase at the same level later. However, the lock-up period until April 18, 2026, for the common shares should be taken into account by potential investors, as it may create temporary price volatility when shares are released back to the market.

Given the increasing awareness and demand for health solutions, Restart Life's strategic investments can yield a favorable return. Nevertheless, investors should remain cautious and conduct thorough due diligence, taking into account any risks associated with early-stage life sciences ventures. Analyzing the company's performance metrics and market positioning over the coming months will be crucial for assessing the sustainability of its growth trajectory. Overall, Restart Life presents a compelling investment opportunity within the life sciences sector, but careful monitoring of market conditions and company developments will be essential.